Healthcare Industry News: S.A.
News Release - September 27, 2012
Alphatec Spine Receives Board Approval to Acquire Assets of Spine Implant Business
CARLS.A., Calif., Sept. 27, 2012 -- (Healthcare Sales & Marketing Network) -- Alphatec Holdings, Inc. (ATEC), the parent company of Alphatec Spine, Inc. (the "Company"), announced today that its board of directors haS.A.proved the Company's plans to acquire certain assets of Phygen, LLC, a spinal implant manufacturer based in Irvine, CA. The purchase price for the assets iS.A.proximately $15.2 million in stock and cash. On August 7, 2012, Alphatec Spine first announced that it had signed a letter of intent to acquire the assets of the company."Since becoming CEO of Alphatec Spine earlier this year, our growth strategy for 2012 and beyond includeS.A.focus on new product launcheS.A.d acquisitions," said Les Cross. "We have since launched new products such as our BridgePoint(TM) Spinous Process Fixation System, acquired exclusive U.S. distribution rights to market a synthetic bone growth biologic under our own brand name of Alphatec NEXoss(TM) and we have plans to acquire certain assets of Phygen, LLC, which we hope to close shortly. It is clear we are executing our new business strategy."
Noted Neurosurgeon, Mark Renfro, M.D., a member of Phygen's Board of Governors, S.A.ed, "Phygen is delighted by this transaction with Alphatec. Upon closing, Phygen will look to bring its innovative product development process, which haS.A.foundation in design input from active spine surgeonS.A.d strategic direction from Phygen's Scientific Advisory Board, into the Alphatec family. All in all, I believe that this proposed transaction iS.A.real win-win for Phygen and Alphatec."
Alphatec Spine said that it expects this transaction to contribute approximately $15 million in revenue in 2013 and be accretive to fully diluted GAAP earnings per S.A.e in 2013. Additional details regarding the transaction will be provided if and when the acquisition is closed. The closing of this transaction is subject to the approval of a majority of the members of Phygen, the execution of the definitive documentS.A.d customary closing conditions set forth in the definitive documents.
About Alphatec Spine
Alphatec Spine, Inc. iS.A.wholly owned subsidiary of Alphatec Holdings, Inc. (ATEC). Alphatec Spine iS.A.medical device company that designs, develops, manufactureS.A.d markets products for the surgical treatment of spine disorders, primarily focused on the aging spine. The Company's mission is to combine world-class customer service with innovative, surgeon-driven products that will help improve the aging patient's quality of life. The Company is poised to achieve its goal through new solutions for patients with osteoporosis, stenosiS.A.d other aging spine deformities, improved minimally invasive productS.A.d techniqueS.A.d integrated biologics solutions. In addition to its U.S. operations, the Company also markets its products in over 50 international markets through itS.A.filiate, Scient'x S.A.S., via a direct sales force in France, Italy and the United Kingdom and via independent distributors in the rest of Europe, the Middle East and Africa. In Latin America, the Company conducts its business through its subsidiary, Cibramed Produtos Medicos. In Japan, the Company markets its products through its subsidiary, Alphatec Pacific, Inc. In the rest of AS.A.and Australia, the Company sells itS.A.d Scient'x's products through itS.A.d Scient'x's distributors.
Forward Looking S.A.ements
This press release may contain "forward-looking S.A.ements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve riskS.A.d uncertainty. Such S.A.ementS.A.e based on management's current expectationS.A.d are subject to a number of riskS.A.d uncertainties that could cause actual results to differ materially from those described in the forward-looking S.A.ements. Alphatec Spine cautions investors that there can be no assurance that actual results or business conditions will not differ materially from those projected or suggested in such forward-looking S.A.ementS.A. a result of various factors. Forward looking S.A.ements include references to the timing, revenue expectationS.A.d earningS.A.cretion from the transaction described in this press release. The words "believe," "will," "should," "expect," "intend," "estimate" and "anticipate," variations of such wordS.A.d similar expressions identify forward-looking S.A.ements, but their absence does not mean that a S.A.ement is not a forward-looking S.A.ement. The important factors that could cause actual operating results to differ significantly from those expressed or implied by such forward-looking S.A.ements include, but are not limited to; the uncertainty of success in closing the acquisition, which still requires the approval of a majority of Phygen's members; failure to achieve or maintain continued acceptance of Alphatec Spine's or Phygen's products by the surgeon community, including without limitation to Alphatec's BridgePoint system and Alphatec NEXoss products; failure to incorporate the Phygen product development process into Alphatec's processeS.A.d systems; failure to achieve anticipated future streamlining and cost savings initiatives related to Alphatec Spine's business; failure to successfully begin in-house manufacturing of certain products; Alphatec Spine'S.A.ility to develop and expand its U.S. and/or global revenues; continuation of favorable third party payor reimbursement for procedures performed using Alphatec Spine's products; unanticipated expenses or liabilities, including those related to the transaction described in this press release, or other adverse eventS.A.fecting cash flow or Alphatec Spine'S.A.ility to successfully control its costs or achieve profitability; uncertainty of additional funding; Alphatec Spine'S.A.ility to compete with other competing productS.A.d with emerging new technologies; product liability exposure; failure to meet all financial obligations in the Cross Medical Settlement or its credit agreement; patent infringement claimS.A.d claims related to Alphatec Spine's intellectual property. Please refer to the risks detailed from time to time in Alphatec Spine's SEC reports, including itS.A.nual Report Form 10-K for the year ended December 31, 2011, filed on March 5, 2012 with the SecuritieS.A.d Exchange Commission, as well as other filings on Form 10-Q and periodic filings on Form 8-K. Alphatec Spine disclaimS.A.y intention or obligation to update or revise any forward-looking S.A.ements, whether aS.A.result of new information, future events, or otherwise, unless required by law.
Source: Alphatec Holdings
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.
RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!